Latest Commercialisation News

Zenith Minerals has completed a pivotal drilling campaign at its Dulcie Far North Gold Project, confirming substantial gold mineralisation and extending resource potential. An updated Mineral Resource Estimate is expected soon, underpinning the company’s development ambitions.

Osteopore Limited has increased its capital raise by drawing down an additional A$500,000 on its Tranche 1 redeemable convertible notes, bringing total subscriptions to A$3.5 million. The funds will support ongoing operations and future growth initiatives.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

HyTerra Limited advances its Nemaha Project with the conversion of the Sue Duroche 3 well into a monitoring site, while preparing to drill the Blythe 13-20 well, marking key steps in its natural hydrogen exploration program.

Kinetiko Energy has begun drilling its third production test well at Brakfontein, applying revised techniques to boost gas recovery ahead of a planned 2026 micro LNG plant launch.

Lake Resources has increased its Measured and Indicated lithium resource at the Kachi Project in Argentina to 8.2 million tonnes LCE, revealing higher-grade lithium zones and enhanced recovery technology. This update strengthens the project's economic outlook amid ongoing feasibility and environmental assessments.

Talga Group has locked in a binding multi-year offtake agreement with Nyobolt for its Talnode-C graphite anode, marking a key commercial milestone for its Vittangi Anode Project in Sweden.

Brazilian Critical Minerals has initiated an in-situ recovery field trial at its Ema Rare Earths Project, aiming to validate the deposit's unique characteristics and advance towards commercial production.

Green Critical Minerals confirms the materiality of a formal sample request from a leading European thermal management provider, underscoring growing market interest in its VHD Graphite technology.

Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.

Optiscan Imaging and the Mayo Clinic have marked a year of significant progress in developing a cutting-edge imaging system designed to enhance robotic-assisted breast cancer surgery.